Inhibikase Therapeutics Inc (IKT)
NASDAQ
Fin d'année 31 Décembre 2023 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Return on Assets (%) | -151.23 | -396.879 | -38.432 | -51.651 | -53.568 | -96.489 |
Return on Equity (%) | 553.213 | 217.274 | -107.594 | -61.353 | -60.736 | -118.883 |
Return on Invested Capital (%) | 178.921 | 172.929 | -96.492 | -60.92 | -61.326 | -126.811 |
Operating Margin (%) | -52.512 | -507.391 | -403.868 | -476.169 | -14678.049 | -7290.805 |
Net Profit Margin (%) | -53.254 | -509.617 | -408.023 | -476.814 | -14678.049 | -7290.805 |
Book Value Per Share | -0.095 | -0.549 | 0.973 | 1.527 | 0.834 | 1.778 |
Earnings Per Share | -0.263 | -0.7 | -0.283 | -0.588 | -0.716 | -3.082 |
Cash Per Share | 0.046 | 0.002 | 1.388 | 1.62 | 0.285 | 1.484 |
Working Capital Per Share | -0.29 | -0.516 | 1.001 | 1.527 | 0.82 | 1.745 |
Operating Profit Per Share | 0.494 | 0.137 | 0.069 | 0.123 | 0.005 | 0.042 |
EBIT Per Share | -0.263 | -0.7 | -0.283 | -0.588 | -0.716 | -3.082 |
EBITDA Per Share | -0.263 | -0.7 | -0.283 | -0.588 | -0.716 | -3.082 |
Free Cash Flow Per Share | -0.263 | -0.7 | -0.283 | -0.588 | -0.706 | -3.109 |
Fin d'année 31 Décembre 2023 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
Inventory Turnover (Days) | N/A | N/A | N/A | N/A | N/A | N/A |
Actions en circulation | 8,18M | 8,18M | 10,05M | 25,16M | 25,23M | N/A |
Fin d'année 31 Décembre 2023 | Déc 2022 | Mar 2023 | Juin 2023 | Sept 2023 | Déc 2023 | Mar 2024 | Juin 2024 | Sept 2024 |
---|---|---|---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |||
Actions en circulation | 25,23M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Assets (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Equity (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Invested Capital (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Operating Margin (%) | N/A | -6889.231 | N/A | N/A | N/A | N/A | N/A | N/A |
Net Profit Margin (%) | N/A | -6889.231 | N/A | N/A | N/A | N/A | N/A | N/A |
Sales Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Earnings Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Cash Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Working Capital Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Operating Profit Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EBIT Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EBITDA Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Free Cash Flow Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Inventory Turnover (Days) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Capitalisation boursière | 129,01M |
Ratio cours/bénéfice | -8,09 |
Ratio prix/ventes | 587,18 |
Ratio prix/liquidités | 16,79 |
Ratio prix/valeur comptable | 14,02 |
Rendement de dividende | - |
Actions en circulation | 67,19M |
Volume moyen (1 semaine) | 324,68k |
Volume moyen (1 mois) | 189,14k |
Variation sur 52 semaines | -29,43% |
Plus haut sur 52 semaines | 4,20 |
Plus bas sur 52 semaines | 1,12 |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales